Congenital Hyperinsulinism (CHI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Congenital Hyperinsulinism (CHI) Market Outlook

Thelansis’s “Congenital Hyperinsulinism (CHI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Congenital Hyperinsulinism treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Congenital Hyperinsulinism (CHI) Overview

Congenital hyperinsulinism (CHI) is an uncommon genetic disorder marked by excessive and uncontrolled insulin release from the pancreas's β-cells, resulting in severe and persistent hypoglycemia. Up to 14 known genetic factors contribute to CHI, while in some cases, CHI is a part of a broader syndrome. The primary cause of severe CHI is typically a mutation in the ABCC8 and KCNJ11 genes. In rarer instances, genetic anomalies affecting the regulation of insulin secretion from pancreatic beta cells can lead to CHI. Since CHI is present from birth, symptoms typically manifest within the first few days of life. Hypoglycemic symptoms encompass floppiness, trembling, feeding difficulties, and drowsiness stemming from low blood sugar levels. Seizures can also occur due to low blood sugar. Loss of consciousness and potential brain injury are possible outcomes without prompt correction of the child's blood glucose levels. Medical treatment using diazoxide or octreotide is employed for preoperative management and in cases where surgery is unsuccessful.

• The estimated incidence of CHI is approximately 1 in every 30,000 individuals. However, it is notably more prevalent in communities where consanguineous marriages are common, with a potential occurrence as frequent as one in every 2,500 children.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: